文献速递湿疹皮炎与荨麻疹

产前鱼油补充、母体COX1基因型与儿童特应性皮炎:一项随机临床试验的二次分析

Prenatal Fish Oil Supplementation, Maternal COX1 Genotype, and Childhood Atopic Dermatitis: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2024-01-01

该研究为丹麦COPSAC2010出生队列的随机临床试验二次分析,纳入635对母子,评估孕期补充n-3 LCPUFA与儿童10岁时特应性皮炎风险的关系。总体补充与安慰剂无差异,但母体COX1 rs1330344基因型与补充存在交互作用:TT型者补充组风险降低,CC型者风险增加。

要点

  • 孕期鱼油补充与儿童AD风险总体无显著关联(HR 1.00)。
  • 母体COX1 TT基因型者补充鱼油可降低儿童AD风险(HR 0.70)。
  • 母体COX1 CC基因型者补充鱼油反而增加儿童AD风险(HR 5.77)。

核心结论

  • 产前n-3 LCPUFA补充与儿童AD风险的关联因母体COX1基因型而异。
  • 研究提示可据此制定仅对TT基因型孕妇补充的个性化预防策略。

研究设计与样本

  • 随机临床试验的预设二次分析,纳入丹麦COPSAC2010出生队列中635对母子,随访至儿童10岁。
  • 736名孕妇在孕24周随机1:1接受每日2.4 g n-3 LCPUFA(鱼油)或安慰剂(橄榄油)至产后1周。

关键数值与推荐

  • 母体COX1 rs1330344 TT基因型者补充鱼油可降低儿童AD风险(HR 0.70,95%CI 0.50-0.98)。
  • 母体COX1 CC基因型者补充鱼油增加儿童AD风险(HR 5.77,95%CI 1.63-20.47)。

临床怎么用

  • 产前鱼油补充预防儿童AD应考虑母体COX1基因型,避免对CC基因型者补充。
  • 对TT基因型孕妇补充鱼油可能作为个性化预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Eicosanoids have a pathophysiological role in atopic dermatitis (AD), but it is unknown whether this is affected by prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA; ie, fish oil) supplementation and genetic variations in the cyclooxygenase-1 (COX1) pathway. OBJECTIVE: To explore the association of n-3 LCPUFA supplementation during pregnancy with risk of childhood AD overall and by maternal COX1 genotype. DESIGN, SETTING, AND PARTICIPANTS: This prespecified secondary analysis of a randomized clinical trial included mother-child pairs from the Danish Copenhagen Prospective Studies on Asthma in Childhood 2010 birth cohort, with prospective follow-up until children were aged 10 years. In the trial, maternal and child COX1 genotypes were determined, and urinary eicosanoids were quantified when the child was 1 year of age. The present study was conducted from January 2019 to December 2021, and data were analyzed from January to September 2023. INTERVENTION: A total of 736 pregnant women at 24 weeks' gestation were randomized 1:1 to 2.4 g of n-3 LCPUFA (fish oil) or placebo (olive oil) per day until 1 week post partum. MAIN OUTCOMES AND MEASURES: Risk of childhood AD until age 10 years overall and by maternal COX1 genotype. RESULTS: At age 10 years, 635 children (91%; 363 [57%] female) completed the clinical follow-up, and these mother-child pairs were included in this study; 321 (51%) were in the intervention group and 314 (49%) in the control group. Pregnancy n-3 LCPUFA supplementation was associated with lower urinary thromboxane A2 metabolites at age 1 year (β, -0.46; 95% CI, -0.80 to -0.13; P = .006), which was also associated with COX1 rs1330344 genotype (β per C allele, 0.47; 95% CI, 0.20-0.73; P = .001). Although neither n-3 LCPUFA supplementation (hazard ratio [HR], 1.00; 95% CI, 0.76-1.33; P = .97) nor maternal COX1 genotype (HR, 0.94; 95% CI, 0.74-1.19; P = .60) was associated with risk of childhood AD until age 10 years, there was evidence of an interaction between these variables (P < .001 for interaction). Among mothers with the TT genotype, risk of AD was reduced in the n-3 LCPUFA group compared with the placebo group (390 mother-child pairs [61%]; HR, 0.70; 95% CI, 0.50-0.98; P = .04); there was no association for mothers with the CT genotype (209 [33%]; HR, 1.29; 95% CI, 0.79-2.10; P = .31), and risk was increased among offspring of mothers with the CC genotype (37 [6%]; HR, 5.77; 95% CI, 1.63-20.47; P = .007). There was a significant interaction between n-3 LCPUFA supplementation and child COX1 genotype and development of AD (P = .002 for interaction). CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial, the association of prenatal n-3 LCPUFA supplementation with risk of childhood AD varied by maternal COX1 genotype. The findings could be used to inform a personalized prevention strategy of providing supplementation only to pregnant individuals with the TT genotype. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00798226.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Chen L, Brustad N, Luo Y, et al. Prenatal Fish Oil Supplementation, Maternal COX1 Genotype, and Childhood Atopic Dermatitis: A Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatol. 2024. PMID: 39196551. doi:10.1001/jamadermatol.2024.2849

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。